Venetoclax is a selective inhibitor of the anti-apoptotic protein BCL-2 that is currently approved for patients with CLL, and is being investigated for patients with R/R FL, MZL and WM as a single agent or in combination with anti-CD20 antibody (67). Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.